Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1981 Mar;78(3):1833–1837. doi: 10.1073/pnas.78.3.1833

Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: Evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a

Craig Gerard 1,2,*, Tony E Hugli 1,2
PMCID: PMC319229  PMID: 6940191

Abstract

A functionally active and potentially lethal fragment of the fifth component of complement (C5) is generated during complement activation in serum from animals of various species. This factor, termed the “classical” anaphylatoxin, was isolated from porcine serum and was identified chemically as the des-Arg derivative of the well-characterized C5a molecule. Unlike the C3a and C4a anaphylatoxins, porcine C5a does not require the COOH-terminal arginyl residue for spasmogenic activity. Further degradation of porcine des-Arg74-C5a by carboxypeptidase Y removed glycine-73 and leucine-72 and decreased the intrinsic spasmogenic activity by >90%. Hence, we conclude that, although the arginyl residue is not essential, the COOH-terminal sequence Leu-Gly-Arg contributes structural information that accounts for >90% of C5a activity. Human des-Arg74-C5a, like its porcine counterpart, has instrinsic anaphylatoxin activity; however, higher concentrations were needed to contract the guinea pig ileal tissue (i.e., 1 μM for human des-Arg74-C5a versus 1 nM for porcine des-Arg74-C5a). Furthermore, the des-Arg form of human C5a was only 0.1% as active as porcine des-Arg74-C5a for enhancing vascular permeability in guinea pig skin. In addition to these biological differences, numerous chemical differences exist between the human and porcine des-Arg74-C5a molecules, the most prominent feature being an oligosaccharide entity associated uniquely with the human C5a. When the oligosaccharide unit of human des-Arg74-C5a was removed by glycosidases, leaving a single glucosamine residue attached to the side chain of asparagine-64, activity was enhanced. The human des-Arg74-C5a molecule devoid of the complex oligosaccharide unit exhibited 10-fold stronger spasmogenic activity and 20- to 50-fold greater permeability-enhancing activity than did human des-Arg74-C5a containing the oligosaccharide. Consequently, the oligosaccharide associated with human C5a modulates or suppresses potentially harmful activities of this anaphylatoxin. The relatively high levels of spasmogenic activity associated with porcine des-Arg74-C5a indicate that this factor is poorly controlled by endogenous serum carboxypeptidase, whereas human C5a is virtually inactivated by the enzyme. Hence, the influence of this oligosaccharide in suppressing human des-Arg74-C5a activity is of major physiologic importance in protecting man from potentially toxic effects of this complement factor.

Keywords: biologically active peptides, chemotatic peptides, glycopeptides

Full text

PDF
1833

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bokisch V. A., Müller-Eberhard H. J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970 Dec;49(12):2427–2436. doi: 10.1172/JCI106462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bokisch V. A., Müller-Eberhard H. J., Cochrane C. G. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med. 1969 May 1;129(5):1109–1130. doi: 10.1084/jem.129.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bose S., Gurari-Rotman D., Ruegg U. T., Corley L., Anfinsen C. B. Apparent dispensability of the carbohydrate moiety of human interferon for antiviral activity. J Biol Chem. 1976 Mar 25;251(6):1659–1662. [PubMed] [Google Scholar]
  4. Caporale L. H., Tippett P. S., Erickson B. W., Hugli T. E. The active site of C3a anaphylatoxin. J Biol Chem. 1980 Nov 25;255(22):10758–10763. [PubMed] [Google Scholar]
  5. Cochrane C. G., Müller-Eberhard H. J. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med. 1968 Feb 1;127(2):371–386. doi: 10.1084/jem.127.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fernandez H. N., Hugli T. E. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol. 1976 Nov;117(5 Pt 1):1688–1694. [PubMed] [Google Scholar]
  7. Fernandez H. N., Hugli T. E. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem. 1978 Oct 10;253(19):6955–6964. [PubMed] [Google Scholar]
  8. Gerard C., Hugli T. E. Amino acid sequence of the anaphylatoxin from the fifth component of porcine complement. J Biol Chem. 1980 May 25;255(10):4710–4715. [PubMed] [Google Scholar]
  9. Gerard C., Hugli T. E. Anaphylatoxin from the fifth component of porcine complement. Purification and partial chemical characterization. J Biol Chem. 1979 Jul 25;254(14):6346–6351. [PubMed] [Google Scholar]
  10. Hugli T. E., Erickson B. W. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin. Proc Natl Acad Sci U S A. 1977 May;74(5):1826–1830. doi: 10.1073/pnas.74.5.1826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jensen J. Anaphylatoxin in its relation to the complement system. Science. 1967 Mar 3;155(3766):1122–1123. doi: 10.1126/science.155.3766.1122. [DOI] [PubMed] [Google Scholar]
  12. Koide N., Muramatsu T. Endo-beta-N-acetylglucosaminidase acting on carbohydrate moieties of glycoproteins. Purification and properties of the enzyme from Diplococcus pneumoniae. J Biol Chem. 1974 Aug 10;249(15):4897–4904. [PubMed] [Google Scholar]
  13. OSLER A. G., RANDALL H. G., HILL B. M., OVARY Z. Studies on the mechanism of hypersensitivity phenomena. III. The participation of complement in the formation of anaphylatoxin. J Exp Med. 1959 Aug 1;110(2):311–339. doi: 10.1084/jem.110.2.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Vogt W., Bodammer G., Lufft E., Schmidt G. Formation of anaphylatoxin in human serum. Experientia. 1969;25(7):744–745. doi: 10.1007/BF01897600. [DOI] [PubMed] [Google Scholar]
  15. Vogt W. Preparation and some properties of anaphylatoxin from hog serum. Biochem Pharmacol. 1968 May;17(5):727–733. doi: 10.1016/0006-2952(68)90009-9. [DOI] [PubMed] [Google Scholar]
  16. Vogt W. The anaphylatoxin-forming system. Ergeb Physiol. 1967;59:160–184. doi: 10.1007/BF02269143. [DOI] [PubMed] [Google Scholar]
  17. Zimmermann B., Damerau B., Vogt W. Purification and partial amino acid sequence of classical anaphylatoxin from pig serum: identification with Des-Arg-C5a. Hoppe Seylers Z Physiol Chem. 1980;361(6):915–924. doi: 10.1515/bchm2.1980.361.1.915. [DOI] [PubMed] [Google Scholar]
  18. da Silva W. D., Eisele J. W., Lepow I. H. Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3. J Exp Med. 1967 Dec 1;126(6):1027–1048. doi: 10.1084/jem.126.6.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES